» Articles » PMID: 10632123

Predictive Factors in Prostate Cancer: Current Concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer

Overview
Specialties Oncology
Urology
Date 2000 Jan 13
PMID 10632123
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Many clinically important predictive factors in prostate cancer are derived from light microscopic examination of tissue specimens by the pathologist. Two separate international consensus conferences held in 1999 addressed the contemporary status of such prognostic factors, sponsored by the College of American Pathologists (CAP) and the World Health Organization (WHO). Both conferences concluded that the following factors are recommended for routine use based on evidence from multiple published trials: TNM stage, histological grade using the Gleason system, surgical margin status, and serum prostate-specific antigen concentration. The WHO conference additionally recommended use of WHO nuclear grade, location of cancer within the prostate, and pathological effects of treatment. Other factors were categorized as promising or of unproven utility, including a wide variety of histopathologic and genetic markers. Standards are needed for analysis and quantitation of methods of tissue analysis, particularly for immunohistochemical studies and genotypic studies. This report describes the recommendations and conclusions of these two conferences.

Citing Articles

Comparison of Diffusion Kurtosis Imaging and Amide Proton Transfer Imaging in the Diagnosis and Risk Assessment of Prostate Cancer.

Yin H, Wang D, Yan R, Jin X, Hu Y, Zhai Z Front Oncol. 2021; 11:640906.

PMID: 33937041 PMC: 8082407. DOI: 10.3389/fonc.2021.640906.


Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review.

Thurtle D, Rossi S, Berry B, Pharoah P, Gnanapragasam V BMJ Open. 2019; 9(6):e029149.

PMID: 31230029 PMC: 6596988. DOI: 10.1136/bmjopen-2019-029149.


Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.

Thurtle D, Greenberg D, Lee L, Huang H, Pharoah P, Gnanapragasam V PLoS Med. 2019; 16(3):e1002758.

PMID: 30860997 PMC: 6413892. DOI: 10.1371/journal.pmed.1002758.


Correlations Between Intratumoral Interstitial Fibrillary Network and Vascular Network in Gleason Patterns of Prostate Adenocarcinoma.

Plesea R, Serbanescu M, Alexandru D, Ciovica V, Stoiculescu A, Pop O Curr Health Sci J. 2018; 41(4):345-355.

PMID: 30538841 PMC: 6243518. DOI: 10.12865/CHSJ.41.04.09.


Androgen Receptor Expression in Epithelial and Stromal Cells of Prostatic Carcinoma and Benign Prostatic Hyperplasia.

Filipovski V, Kubelka-Sabit K, Jasar D, Janevska V Open Access Maced J Med Sci. 2017; 5(5):608-612.

PMID: 28932300 PMC: 5591589. DOI: 10.3889/oamjms.2017.151.